Imedex® is an industry leader in providing certified, independent continuing medical education to health care professionals.

3-4 March 2017

Madrid, Spain

Symposia


Friday, 3 March 2017

HOW I OPTIMIZE TREATMENT FOR MY NSCLC PATIENTS WITH ADVANCED AND AGGRESSIVE DISEASE

11:40–13:10
Hotel Meliá Avenida América, Hall Zaragoza III & IV
Madrid, Spain

http://lungcancer.elsevierresource.com


Dear Colleague,

We warmly welcome you to this satellite symposium, How I optimize treatment for my NSCLC patients with advanced and aggressive disease, which will take place on Friday 3 March 2017 at 11:40, during the 18th European Congress: Perspectives in Lung Cancer (PILC) in Madrid, Spain.

Our distinguished faculty of experts, internationally recognized for their experience and knowledge in the field of non-small-cell lung cancer (NSCLC), will discuss improving the treatment of squamous and non-squamous NSCLC in view of the high unmet medical need. With the use of patient cases from their clinical practices, the experts will illustrate current best clinical practices and potential new treatment options for patients with advanced and aggressive NSCLC.

The symposium will be interactive, with ample opportunity for you to provide input. We invite you to share your opinions and submit questions; this exchange of experience and knowledge will foster new insights into potential therapies for our patients. We hope that you find this symposium informative and rewarding, and an enjoyable experience.

Yours sincerely,

Silvia Novello, MD, PhD
Chair

 

SCIENTIFIC AGENDA

11:30

Welcome and introduction
Silvia Novello, MD, PhD

11:45

How I select the right treatment for the right patient: histological and molecular profiling challenges
Fernando Lopez-Rios, MD, PhD

12:05

How I optimize treatment for my patients with advanced non-squamous
NSCLC: present options and future perspectives

Joachim G.J.V. Aerts, PhD

12:35

How I optimize treatment for my patients with advanced squamous
NSCLC: present options and future perspectives

Luis Paz-Ares, MD, PhD

13:05

Summary and key learning points
Silvia Novello, MD, PhD

 
 

Elsevier and Lilly